US 12,405,287 B2
Lung cancer detection kit or device, and detection method
Hiroko Sudo, Kamakura (JP); Hitoshi Nobumasa, Kamakura (JP); Satoko Kozono, Kamakura (JP); Satoshi Kondou, Kamakura (JP); Junpei Kawauchi, Kamakura (JP); Atsushi Ochiai, Kashiwa (JP); and Motohiro Kojima, Kashiwa (JP)
Assigned to TORAY INDUSTRIES, INC., Tokyo (JP); and NATIONAL CANCER CENTER, Tokyo (JP)
Filed by TORAY INDUSTRIES, INC., Tokyo (JP); and NATIONAL CANCER CENTER, Tokyo (JP)
Filed on Jan. 5, 2024, as Appl. No. 18/405,371.
Application 18/405,371 is a division of application No. 17/977,377, filed on Oct. 31, 2022, granted, now 12,117,462.
Application 17/977,377 is a division of application No. 16/800,755, filed on Feb. 25, 2020, granted, now 11,519,927, issued on Dec. 6, 2022.
Application 16/800,755 is a division of application No. 15/319,695, granted, now 10,620,228, issued on Apr. 14, 2020, previously published as PCT/JP2015/067533, filed on Jun. 18, 2015.
Claims priority of application No. 2014-125561 (JP), filed on Jun. 18, 2014.
Prior Publication US 2024/0183875 A1, Jun. 6, 2024
Int. Cl. C12Q 1/68 (2018.01); C12M 1/00 (2006.01); C12N 15/09 (2006.01); C12P 19/34 (2006.01); G01N 37/00 (2006.01)
CPC G01N 37/00 (2013.01) [C12M 1/00 (2013.01); C12N 15/09 (2013.01); C12Q 1/68 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01)] 6 Claims
 
1. A method for detecting lung cancer in a human subject, comprising
measuring an expression level of hsa-miR-4258 in a blood, serum, or plasma sample from the subject;
comparing the measured expression level of hsa-miR-4258 to a control expression level for a healthy subject;
detecting decreased level of hsa-miR-4258 in the sample from the subject as compared to the control expression level from the sample from the healthy subject;
wherein the decreased level of hsa-miR-4258 indicates that the subject has lung cancer; and
wherein the method further comprises treating the subject for the lung cancer or performing a diagnostic procedure on the subject with the lung cancer;
wherein the treatment comprises surgery, radiotherapy, chemotherapy or a combination thereof; and
wherein the diagnostic procedure comprises chest X-ray examination or diagnostic imaging of the lung of the human subject.